336 related articles for article (PubMed ID: 25458970)
1. A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.
Barron AJ; Klinger C; Shah SM; Wright JS
Health Policy; 2015 Feb; 119(2):137-46. PubMed ID: 25458970
[TBL] [Abstract][Full Text] [Related]
2. A regulatory governance perspective on Health Technology Assessment (HTA) in Sweden.
Shah SM; Barron A; Klinger C; Wright JS
Health Policy; 2014 May; 116(1):27-36. PubMed ID: 24655685
[TBL] [Abstract][Full Text] [Related]
3. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
4. Regulatory space and the contextual mediation of common functional pressures: analyzing the factors that led to the German Efficiency Frontier approach.
Klingler C; Shah SM; Barron AJ; Wright JS
Health Policy; 2013 Mar; 109(3):270-80. PubMed ID: 23380191
[TBL] [Abstract][Full Text] [Related]
5. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
6. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
Allen N; Pichler F; Wang T; Patel S; Salek S
Health Policy; 2013 Dec; 113(3):305-12. PubMed ID: 24176288
[TBL] [Abstract][Full Text] [Related]
7. [Hospital-based health technology assessment in France: how to proceed to evaluate innovative medical devices?].
Martelli N; van den Brink H; Denies F; Dervaux B; Germe AF; Prognon P; Pineau J
Ann Pharm Fr; 2014 Jan; 72(1):3-14. PubMed ID: 24438663
[TBL] [Abstract][Full Text] [Related]
8. "It all depends": conceptualizing public involvement in the context of health technology assessment agencies.
Gauvin FP; Abelson J; Giacomini M; Eyles J; Lavis JN
Soc Sci Med; 2010 May; 70(10):1518-26. PubMed ID: 20207061
[TBL] [Abstract][Full Text] [Related]
9. The Development of the Romanian Scorecard HTA System.
Radu CP; Chiriac ND; Pravat AM
Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
11. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
12. [HTA in the decision-making processes of health care institutions. Current state and relevant questions of regulatory health law].
Francke R; Hart D
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):241-50. PubMed ID: 16482461
[TBL] [Abstract][Full Text] [Related]
13. Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India.
Dabak SV; Pilasant S; Mehndiratta A; Downey LE; Cluzeau F; Chalkidou K; Luz ACG; Youngkong S; Teerawattananon Y
Health Res Policy Syst; 2018 Nov; 16(1):115. PubMed ID: 30486827
[TBL] [Abstract][Full Text] [Related]
14. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
[TBL] [Abstract][Full Text] [Related]
15. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
Hao Y; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
[TBL] [Abstract][Full Text] [Related]
16. Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.
Lehoux P; Miller FA; Daudelin G; Denis JL
Int J Health Policy Manag; 2017 Sep; 6(9):509-518. PubMed ID: 28949463
[TBL] [Abstract][Full Text] [Related]
17. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
[TBL] [Abstract][Full Text] [Related]
18. New trends and challenges in the European regulation of innovative medicines.
Enzmann H
Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
[TBL] [Abstract][Full Text] [Related]
19. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
[TBL] [Abstract][Full Text] [Related]
20. INTRODUCTION OF INNOVATIVE MEDICAL DEVICES AT FRENCH UNIVERSITY HOSPITALS: AN OVERVIEW OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT INITIATIVES.
Martelli N; Billaux M; Borget I; Pineau J; Prognon P; van den Brink H
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):12-8. PubMed ID: 25991072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
